The enhanced transcriptional activity of the V-val subtype of Epstein-Barr virus nuclear antigen 1 in epithelial cell lines

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1417-1424

  Mai, Shi Juan ^a   Xie, Dan ^a   Huang, Yu Fan ^a   Wang, Feng Wei ^a   Liao, Yi Ji ^a   Deng, Hai Xia ^a   Liu, Wen Ju ^a   Hua, Wen Feng ^a   Zeng, Yi Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

EBNA1; EBV.; Sequence variation; Transcriptional activation

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; LUCIFERASE; UNCLASSIFIED DRUG; V VAL EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 1;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CONTROLLED STUDY; DNA BINDING; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE MUTATION; GENE VECTOR; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; REPORTER GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION;

BINDING SITES; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; DNA; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; HUMANS; LUCIFERASES; MUTATION; NASOPHARYNGEAL NEOPLASMS; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 77950827326     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000779     Document Type: Article

References (30)

1. Kieff E and Rickinson AB: Epstein-Barr virus and its replication. In: Fields Virology. 4th edition. Knipe DM and Howley PM (ed.) Lippincott Williams and Wilkins Publications Corp., Philadelphia, pp2511-2574, 2001.
2. Gahn TA and Schildkraut CL: The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 58: 527-535, 1989.
3. Niller HH, Glaser G, Knüchel R and Wolf H: Nucleoprotein complexes and DNA 5'-ends at oriP of Epstein-Barr virus. J Biol Chem 270: 12864-12868, 1995.
4. Lupton S and Levine AJ: Mapping of genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol 5: 2533-2542, 1985.
5. Gahn TA and Sugden B: An EBNA1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene. J Virol 69: 2633-2636, 1995.
6. Puglielli MT, Desai N and Speck SH: Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp). J Virol 71: 120-128, 1997.
7. Sugden B and Warren N: A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol 63: 2644-2649, 1989.
8. Nonkwelo C, Skinner J, Bell A, Rickinson A and Sample J: Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70: 623-627, 1996.
9. Baer R, Bankier AT, Biggin MD, Deininger P, Farrell PJ, Gibson T, Hudson G, Satchwell S, Seguin C, Tuffnell P and Barrel B: DNA sequence and expression of the B95-8 Epstein- Barr virus genome. Nature 310: 207-211, 1984.
10. Hung SC, Kang MS and Kieff E: Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci USA 98: 1865-1870, 2001.
11. Bhatia K, Raj A, Guitierrez MI, Judde JG, Spangler G, Venkatesh H and Magrath IT: Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas. Oncogene 13: 177-181, 1996.
12. Snudden DK, Smith PR, Lai D, Ng MH and Griffin BE: Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. Oncogene 10: 1545-1552, 1995.
13. Wang WY, Chien YC, Jan JS, Chueh CM and Lin JC: Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal carcinoma. Clin Cancer Res 8: 2586-2590, 2002.
14. Mai SJ, Zhang XS, Li DJ, Shen GP, Jiang JH, Zhang RH, Yu XJ, Chen SP and Zeng YX: The character of EBNA1 gene variation in Cantonese and its association with nasopharyngeal carcinoma. Chin Sci Bull 49: 2640-2643, 2004.
15. Zhang XS, Wang HH, Hu LF, Li A, Zhang RH, Mai HQ, Xia JC, Chen LZ and Zeng YX: V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. Cancer Lett 211: 11-18, 2004.
16. Mai SJ, Ooka T, Li DJ, Shen GP, Jiang JH, Zhang RH, Yu XJ, Chen SP and Zeng YX: Functional advantage of NPC-related V-val subtype of Epstein-Barr virus nuclear antigen 1 compared with prototype in epithelial cell line. Oncol Rep 17: 141-146, 2007.
17. Yates JL and Camiolo SM: Dissection of DNA replication and enhancer activation functions of Epstein-Barr virus nuclear antigen 1. Cancer Cells 6: 197-205, 1988.
18. Zeng MS, Li DJ, Liu QL, Song LB, Li MZ, Zhang RH, Yu XJ, Wang HM, Ernberg I and Zeng YX: Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 79: 15323-15330, 2005.
19. Do NV, Ingemar E, Phi PT, Jenny A, Chinh TT, Zeng Y and Hu L: A major EBNA1 variant from Asian EBV isolates shows enhanced transcriptional activity compared to prototype B95.8. Virus Res 132: 15-24, 2008.
20. Bochkarev A, Barwell JA, Pfuetzner RA, Furey W Jr, Edwards AM and Frappier L: Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1. Cell 83: 39-46, 1995.
21. Ceccarelli DF and Frappier L: Functional analyses of the EBNA1 origin DNA binding protein of Epstein-Barr virus. J Virol 74: 4939-4948, 2000.
22. Wu H, Kapoor P and Frappier L: Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J Virol 76: 2480-2490, 2002.
23. Kanda T, Otter M and Wahl GM: Coupling of mitotic chromosome tethering and replication competence in Epstein-Barr virus-based plasmids. Mol Cell Biol 21: 3576-3588, 2001.
24. Wysokenski DA and Yates JL: Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol 63: 2657-2666, 1989.
25. Schaefer BC, Strominger JL and Speck SH: Hostcell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol 17: 364-377, 1997.
26. Altmann M, Pich D, Ruiss R, Wang J, Sugden B and Hammerschmidt W: Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci USA 103: 14188-14193, 2006.
27. Srinivas SK and Sixbey JW: Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol 69: 8155-8158, 1995.
28. Kube D, Vockerodt M, Weber O, Hell K, Wolf J, Haier B, Grässer FA, Müller-Lantzsch N, Kieff E, Diehl V and Tesch H: Expression of Epstein-Barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. J Virol 73: 1630-1636, 1999.
29. Kuhn-Hallek I, Sage DR, Stein L, Groelle H and Fingeroth JD: Expression of recombination activating genes (RAG-1 and RAG-2) in Epstein-Barr virus-bearing B cells. Blood 85: 1289-1299, 1995.
30. Wood VH, O'Neil JD, Wei W, Stewart SE, Dawson CW and Young LS: Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFbeta signaling pathways. Oncogene 26: 4135-4147, 2007.